

Fabio Cacciapaglia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1187061/publications.pdf>

Version: 2024-02-01

74
papers

1,069
citations

516710

16
h-index

477307

29
g-index

76
all docs

76
docs citations

76
times ranked

1611
citing authors

#	ARTICLE	IF	CITATIONS
1	Adipokines and Systemic Lupus Erythematosus: Relationship with Metabolic Syndrome and Cardiovascular Disease Risk Factors. <i>Journal of Rheumatology</i> , 2009, 36, 295-297.	2.0	92
2	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients's subgroups. <i>Journal of Autoimmunity</i> , 2021, 125, 102744.	6.5	83
3	Portosystemic shunts in a large cohort of patients with liver cirrhosis: detection rate and clinical relevance. <i>Journal of Gastroenterology</i> , 2009, 44, 76-83.	5.1	66
4	Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study). <i>Autoimmunity Reviews</i> , 2009, 8, 309-315.	5.8	54
5	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. <i>Autoimmunity Reviews</i> , 2011, 10, 631-635.	5.8	50
6	Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. <i>Lupus</i> , 2009, 18, 249-256.	1.6	45
7	Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. <i>International Immunopharmacology</i> , 2005, 5, 437-459.	3.8	41
8	Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus. <i>Internal and Emergency Medicine</i> , 2013, 8, 705-712.	2.0	41
9	Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 108-114.	3.4	37
10	Inflammation and iron metabolism in adult patients with epilepsy: Does a link exist?. <i>Epilepsy Research</i> , 2013, 107, 244-252.	1.6	32
11	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 440-441.	0.9	32
12	Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	30
13	Alexithymia and Neuroendocrine- Immune Response in Patients with Autoimmune Diseases: Preliminary Results on Relationship between Alexithymic Construct and TNF- α Levels. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 208-211.	3.8	28
14	Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1599-1606.	1.9	24
15	Lack of Effect of Vitamin D Administration during Pregnancy and Early Life on Diabetes Incidence in the Non-obese Diabetic Mouse. <i>Hormone and Metabolic Research</i> , 2004, 36, 620-624.	1.5	23
16	Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. <i>RMD Open</i> , 2022, 8, e001847.	3.8	19
17	Selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline-rich isocortical but not prefrontal areas: dependence on serotonin-1A receptors and independence from noradrenergic innervation. <i>Journal of Neurochemistry</i> , 2005, 93, 371-382.	3.9	18
18	Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment. <i>Clinical Rheumatology</i> , 2019, 38, 2355-2362.	2.2	15

#	ARTICLE	IF	CITATIONS
19	A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 1309-1317.	2.2	15
20	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
21	A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents. <i>Journal of Clinical Rheumatology</i> , 2021, Publish Ahead of Print, .	0.9	14
22	C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis. <i>European Journal of Internal Medicine</i> , 2022, 104, 49-54.	2.2	14
23	Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response. <i>Drug Development Research</i> , 2014, 75, S77-80.	2.9	13
24	Influence of TNF- α inhibition on oxidative stress of rheumatoid arthritis patients. <i>Reumatismo</i> , 2015, 67, 97-102.	0.9	12
25	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
26	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic Disease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	2.2	12
27	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
28	Pulmonary arterial hypertension: guidelines and unmet clinical needs. <i>Reumatismo</i> , 2021, 72, 228-246.	0.9	10
29	Body mass index and adipokines/cytokines dysregulation in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2021, 206, 153-160.	2.6	10
30	The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e145-e149.	0.9	10
31	Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 762-767.	0.8	10
32	Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102866.	6.5	10
33	Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 1188-1188.	1.9	9
34	Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2022, 49, 334-335.	2.0	9
35	Postmeal portal flow variations in HCV-related chronic hepatitis and liver cirrhosis with and without hyperdynamic syndrome. <i>In Vivo</i> , 2008, 22, 509-12.	1.3	9
36	Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 353.	2.5	9

#	ARTICLE	IF	CITATIONS
37	The Use of an Interferon-Gamma Release Assay as a Biomarker of Response to Anti-TNF-Alpha Treatment. Drug Development Research, 2014, 75, S50-S53.	2.9	8
38	Serum osteopontin negatively impacts on intima-media thickness in patients with systemic lupus erythematosus. European Journal of Clinical Investigation, 2019, 49, e13089.	3.4	8
39	Spontaneous splenorenal shunt in a patient with antiphospholipid syndrome: the first case reported. Lupus, 2007, 16, 56-58.	1.6	7
40	Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox. Cardiovascular Toxicology, 2014, 14, 387-392.	2.7	7
41	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. Clinical Rheumatology, 2022, 41, 2261-2267.	2.2	7
42	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. Current Pharmaceutical Design, 2022, 28, 2022-2028.	1.9	7
43	Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast. Clinical and Experimental Immunology, 2020, 201, 200-204.	2.6	6
44	Predictors of long-term clinical remission in rheumatoid arthritis. European Journal of Clinical Investigation, 2021, 51, e13363.	3.4	6
45	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. Annals of the Rheumatic Diseases, 2021, 80, 1498-1501.	0.9	6
46	Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis. Journal of International Medical Research, 2016, 44, 28-32.	1.0	5
47	The natural history of insulin content in the pancreas of female and male non-obese diabetic mouse: implications for trials of diabetes prevention in humans. Diabetes/Metabolism Research and Reviews, 2004, 20, 394-398.	4.0	4
48	Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy. Rheumatology, 2019, 58, 440-440.	1.9	4
49	Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2020, 79, e104-e104.	0.9	4
50	Serum adiponectin levels are associated with presence of carotid plaque in women with systemic lupus erythematosus. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1147-1151.	2.6	4
51	Apoptosis and Autoimmunity Induced by Clodronate in Systemic Lupus Erythematosus Mononuclear Circulating Cells. International Journal of Immunopathology and Pharmacology, 2010, 23, 535-542.	2.1	3
52	Atherosclerosis and Autoimmunity. Mediators of Inflammation, 2018, 2018, 1-2.	3.0	3
53	Matters of the Heart: The Case of TNF-Targeting Drugs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 79-87.	3.4	3
54	Percutaneous ultrasound-guided ablation of BW7756-hepatoma using ethanol or acetic acid in a rat model. BMC Gastroenterology, 2007, 7, 45.	2.0	2

#	ARTICLE	IF	CITATIONS
55	Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13343.	3.4	2
56	High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry. <i>Clinical Rheumatology</i> , 2021, 40, 3659-3665.	2.2	2
57	Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. <i>Internal and Emergency Medicine</i> , 2022, 17, 475-480.	2.0	2
58	Complete Hydatidiform Mole Mimicking Sacroiliitis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e122-e122.	0.9	2
59	The use of a glucose spray device to control progression towards hypoglycaemia. <i>Endocrine</i> , 2012, 42, 442-444.	2.3	1
60	Section 3: Rheumatoid Arthritis. <i>Clinical Drug Investigation</i> , 2013, 33, 113-132.	2.2	1
61	AB0608...TOCILIZUMAB TREATMENT FOR LARGE VESSELS VASCULITIS: REAL LIFE PRELIMINARY EXPERIENCES. , 2019, , .		1
62	Correspondence on "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry" by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e159-e159.	0.9	1
63	Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 210-218.	1.7	1
64	Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients. <i>Rheumatology</i> , 2020, 59, 1442-1444.	1.9	1
65	Successful treatment with anakinra of refractory pericarditis in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 227.	0.8	1
66	New technologies aiding dietary programmes for weight control: the oral glucose spray. <i>Endocrine</i> , 2014, 45, 288-292.	2.3	0
67	Possible role of adipocytokines in systemic sclerosis-associated small pericardial effusion. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 153-158.	1.7	0
68	AB0245...PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE). , 2019, , .		0
69	AB0600...APREMILAST EFFECTIVENESS IN REFRACTORY ORAL AND GENITAL ULCERS OF BEHÇET'S DISEASE: DATA FROM REAL LIFE SETTINGS. , 2019, , .		0
70	AB0640...SURVIVAL AND MORTALITY PREDICTORS IN SYSTEMIC SCLEROSIS: RESULTS FROM A MONOCENTRIC ITALIAN COHORT. , 2019, , .		0
71	FRI0070...SHORT-TERM INFLAMMATORY AND LIPIDS CHANGES IN RHEUMATOID ARTHRITIS PATIENTS INFLUENCE CARDIOVASCULAR RISK ALGORITHMS: A MONOCENTRIC RETROSPECTIVE STUDY. , 2019, , .		0
72	Response to: "Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro et al" by Agca et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e106-e106.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e102-e102.	0.9	0
74	Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1147-1148.	0.8	0